FireCyte Therapeutics
A neuroscience-focused ophthalmology company developing multi-target fusion protein therapeutics for retinal neurodegenerative diseases. The organization combines target identification and validation in neuroinflammation with protein engineering to create intravitreally delivered biologics that modulate microglial activation and directly protect retinal neurons. Activities span target discovery, preclinical efficacy testing in ocular models, and translational collaborations with academic clinical groups.
Industries
Nr. of Employees
small (1-50)
Products
Multi-target fusion proteins based on an endogenous CNS protein
Engineered therapeutic proteins designed to simultaneously modulate inflammatory receptors and neuronal survival receptors for retinal neuroprotection; formatted for intravitreal delivery to posterior-segment eye diseases.
Multi-target fusion proteins based on an endogenous CNS protein
Engineered therapeutic proteins designed to simultaneously modulate inflammatory receptors and neuronal survival receptors for retinal neuroprotection; formatted for intravitreal delivery to posterior-segment eye diseases.
Expertise Areas
- Ocular neurodegeneration and glaucoma
- Neuroinflammation and microglia modulation
- Protein therapeutic design and engineering
- Intravitreal drug delivery
Key Technologies
- Fusion protein engineering
- Receptor-targeted biologics (SORT1, DCC)
- iPSC-derived functional assays
- Intravitreal administration
News & Updates
Poster on discovery of IGFBPL1-fusion proteins as multifunctional therapeutics for retinal degenerative disorders; reported use of target identification, domain mapping, SAR and iPSC-based pharmacology benchmarking.
Foundational publication reporting the role of IGFBPL1 in microglia homeostasis and implications for glaucoma and tauopathy.
Representative foundational research describing immune mechanisms contributing to glaucoma progression.
Publication demonstrating modulation of retinal immune environment to support visual recovery in an optic neuropathy model.
Clinical/observational publication linking immune markers with retinal structural measures in glaucoma patients.
Poster on discovery of IGFBPL1-fusion proteins as multifunctional therapeutics for retinal degenerative disorders; reported use of target identification, domain mapping, SAR and iPSC-based pharmacology benchmarking.
Foundational publication reporting the role of IGFBPL1 in microglia homeostasis and implications for glaucoma and tauopathy.
Representative foundational research describing immune mechanisms contributing to glaucoma progression.
Publication demonstrating modulation of retinal immune environment to support visual recovery in an optic neuropathy model.
Clinical/observational publication linking immune markers with retinal structural measures in glaucoma patients.